Article Text

PDF
Longitudinal quantification of aqueous flare and cells in Vogt–Koyanagi–Harada disease
  1. W Fang1,2,3,
  2. H Zhou1,2,3,
  3. P Yang1,2,3,
  4. X Huang1,2,3,
  5. L Wang1,2,3,
  6. A Kijlstra2,4
  1. 1
    Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, PR China
  2. 2
    Uveitis Study Center of Sun Yat-sen University and International Uveitis Study Laboratory of Guangdong Province, Guangzhou, PR China
  3. 3
    State Key Laboratory of Ophthalmology of Sun Yat-sen University, Guangzhou, PR China
  4. 4
    Eye Research Institute Maastricht, Department of Ophthalmology, University Hospital Maastricht, Maastricht, The Netherlands
  1. Prof.Dr. P Yang, Zhongshan Ophthalmic Center, Xianlie Road 54, Guangzhou 510060, PR China; peizengyang{at}hotmail.com

Abstract

Aims: To quantitatively evaluate the changes of aqueous flare and cells in eyes with Vogt–Koyanagi–Harada (VKH) disease.

Methods: This prospective study included 35 initial-onset VKH patients (70 eyes) and 46 recurrent VKH patients (92 eyes) following immunotherapy. Aqueous flare and cells were quantified using the laser flare-cell meter before treatment, 2 weeks, 1, 3, 6 and 9 months after treatment.

Results: Before treatment, mean aqueous flare (ph/ms) in initial-onset and recurrent VKH eyes were 8.1 (SD 4.1) vs 43.6 (20.7) (p = 0.000). Following treatment, recurrent VKH eyes showed a significantly higher flare value than initial-onset VKH eyes at 2 weeks, 1, 3 and 6 months. Prior to treatment, mean cell counts (cells/0.5 mm3) in initial-onset and recurrent VKH eyes were 2.0 (1.9) vs 39.4 (23.1) (p = 0.000). Following treatment, recurrent VKH eyes showed significantly higher cell counts than initial-onset VKH eyes at 2 weeks, 1 and 3 months.

Conclusions: Our study shows that recurrent VKH patients displayed a more striking and long-lasting breakdown of the BAB and more severe inflammation than initial-onset VKH patients. Our study also indicates that the disruption of BAB lasted longer than aqueous cells either in initial-onset or in recurrent VKH patients.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared.

  • Funding: This study was supported in part by the Fund for Project of Science and Technology of Guangdong province (2005B60302009), Key Project of Natural Science Foundation (30630064), National supporting project of PR China and “5010” Clinical Project of Sun Yat-sen University.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.